The study will assess the immune response and safety of the new vaccine against the Zaire and Sudan species of Ebola. The vaccine is based on the ChAdOx1 virus, a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine – or the Oxford-AstraZeneca vaccine. ‘This study will provide valuable data on the safety and immunological aspects of a novel multivalent Ebolavirus ChAdOx1 vaccine.’Volunteers interested in enrolling on the study can do so online. A further trial for the vaccine is planned to commence in Tanzania by the end of 2021.
